<DOC>
	<DOCNO>NCT01076075</DOCNO>
	<brief_summary>This study evaluate whether addition Sitagliptin treatment provide great decrease A1C level compare placebo participant inadequate glycemic control sulfonylurea metformin combination therapy .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Sitagliptin 100 mg Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control ( MK-0431-229 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<criteria>Type 2 diabetes mellitus Hemoglobin A1C ≥7.5 % ≤10.5 % Currently take stable dose metformin ( least 1500 mg/day ) either glimepiride ( least 2 mg/day ) gliclazide ( least 50 % maximum register dose ) least 10 week prior study start Male , female highly unlikely conceive Type 1 diabetes mellitus ketoacidosis Taking dipeptidyl peptidase4 ( DPP4 ) inhibitor ( sitagliptin ) glucagonlike peptide1 ( GLP1 ) mimetic ( exenatide liraglutide ) require insulin therapy within 12 week prior study start On weight loss program maintenance phase weight loss medication History liver disease , heart failure , heart disease , stroke , high blood pressure , blood disorder , cancer HIV positive Pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>